<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "5: Operation ", fill: "#0087bd"},
{source: "5: Operation ", target: "5: Annual Report", fill: "#0087bd"},
{source: "5: Operation ", target: "7: distribution", fill: "#87ceeb"},
{source: "7: distribution", target: "7: expectations", fill: "#87ceeb"},
{source: "7: expectations", target: "7: distributor", fill: "#87ceeb"},
{source: "7: distributor", target: "7: inventories", fill: "#87ceeb"},
{source: "7: inventories", target: "7: consumption", fill: "#87ceeb"},
{source: "7: distribution", target: "8: could affect", fill: "#674846"},
{source: "8: could affect", target: "8: seasonal fluctuations", fill: "#674846"},
{source: "8: seasonal fluctuations", target: "8: Group A Strep ", fill: "#674846"},
{source: "8: Group A Strep ", target: "8: generally", fill: "#674846"},
{source: "8: generally", target: "8: third calendar quarters", fill: "#674846"},
{source: "8: third calendar quarters", target: "8: fourth calendar quarters", fill: "#674846"},
{source: "8: fourth calendar quarters", target: "8: recent media attention focused on", fill: "#674846"},
{source: "8: recent media attention focused on", target: "8: potential influenza pandemic", fill: "#674846"},
{source: "8: potential influenza pandemic", target: "8: uncertainty surrounding", fill: "#674846"},
{source: "8: uncertainty surrounding", target: "8: detection", fill: "#674846"},
{source: "8: detection", target: "8: competition such as would", fill: "#674846"},
{source: "8: competition such as would", target: "8: better financed competitors introduced", fill: "#674846"},
{source: "8: better financed competitors introduced", target: "8: compete with one", fill: "#674846"},
{source: "8: compete with one", target: "8: economic conditions", fill: "#674846"},
{source: "8: economic conditions", target: "8: international", fill: "#674846"},
{source: "8: international", target: "8: currency fluctuations", fill: "#674846"},
{source: "8: currency fluctuations", target: "8: sales levels since", fill: "#674846"},
{source: "8: sales levels since", target: "8: significant", fill: "#674846"},
{source: "8: significant", target: "8: costs with", fill: "#674846"},
{source: "8: costs with", target: "8: relatively higher sales could likely", fill: "#674846"},
{source: "8: relatively higher sales could likely", target: "8: reduce costs by", fill: "#674846"},
{source: "8: reduce costs by", target: "8: same proportion", fill: "#674846"},
{source: "8: same proportion", target: "8: hence could", fill: "#674846"},
{source: "8: hence could", target: "8: market penetration", fill: "#674846"},
{source: "8: market penetration", target: "8: new products", fill: "#674846"},
{source: "8: new products", target: "8: distributors", fill: "#674846"},
{source: "8: distributors", target: "8: inventories", fill: "#674846"},
{source: "8: inventories", target: "8: distribution channels", fill: "#674846"},
{source: "8: distribution channels", target: "8: distributor buying patterns", fill: "#674846"},
{source: "8: could affect", target: "28: Management ", fill: "#b666d2"},
{source: "28: Management ", target: "28: aggregate will", fill: "#b666d2"},
{source: "28: Management ", target: "30: litigation", fill: "#fdee00"},
{source: "30: litigation", target: "30: proprietary", fill: "#fdee00"},
{source: "30: proprietary", target: "30: technology", fill: "#fdee00"},
{source: "30: technology", target: "30: adversely", fill: "#fdee00"},
{source: "30: adversely", target: "30: litigation may", fill: "#fdee00"},
{source: "30: litigation may", target: "30: distributors", fill: "#fdee00"},
{source: "30: distributors", target: "30: reduce purchases", fill: "#fdee00"},
{source: "30: reduce purchases", target: "30: may consume", fill: "#fdee00"},
{source: "30: may consume", target: "30: outcome would", fill: "#fdee00"},
{source: "30: outcome would", target: "30: court may find", fill: "#fdee00"},
{source: "30: court may find", target: "30: thirdparty", fill: "#fdee00"},
{source: "30: thirdparty", target: "30: infringed by", fill: "#fdee00"},
{source: "30: infringed by", target: "30: adverse outcome could", fill: "#fdee00"},
{source: "30: adverse outcome could", target: "30: significant liability", fill: "#fdee00"},
{source: "30: significant liability", target: "30: past royalty payments penalties special", fill: "#fdee00"},
{source: "30: past royalty payments penalties special", target: "30: punitive damages", fill: "#fdee00"},
{source: "30: punitive damages", target: "30: andor future royalty payments significantly affecting", fill: "#fdee00"},
{source: "30: andor future royalty payments significantly affecting", target: "30: future earnings", fill: "#fdee00"},
{source: "30: future earnings", target: "30: necessary license upon", fill: "#fdee00"},
{source: "30: necessary license upon", target: "30: us from selling", fill: "#fdee00"},
{source: "30: us from selling", target: "30: court could award", fill: "#fdee00"},
{source: "30: court could award", target: "30: preliminary andor permanent injunction which", fill: "#fdee00"},
{source: "30: preliminary andor permanent injunction which", target: "30: would prevent us from selling", fill: "#fdee00"},
{source: "30: would prevent us from selling", target: "30: future products", fill: "#fdee00"},
{source: "30: litigation", target: "34: cannot continue", fill: "#b39eb5"},
{source: "34: cannot continue", target: "34: protect proprietary technology", fill: "#b39eb5"},
{source: "34: protect proprietary technology", target: "34: profits could", fill: "#b39eb5"},
{source: "34: profits could", target: "34: adversely affected", fill: "#b39eb5"},
{source: "34: cannot continue", target: "47: successfully introduce new technologies new", fill: "#96ded1"},
{source: "47: successfully introduce new technologies new", target: "47: new markets could", fill: "#96ded1"},
{source: "47: successfully introduce new technologies new", target: "49: development", fill: "#cf0"},
{source: "49: development", target: "49: manufacture", fill: "#cf0"},
{source: "49: manufacture", target: "49: diagnostic products", fill: "#cf0"},
{source: "49: diagnostic products", target: "49: significant investment", fill: "#cf0"},
{source: "49: development", target: "54: past come primarily from", fill: "#da70d6"},
{source: "54: past come primarily from", target: "54: operations", fill: "#da70d6"},
{source: "54: operations", target: "54: capital line", fill: "#da70d6"},
{source: "54: past come primarily from", target: "91: testing manufacture", fill: "#ff6700"},
{source: "91: testing manufacture", target: "91: by numerous governmental authorities", fill: "#ff6700"},
{source: "91: by numerous governmental authorities", target: "91: principally", fill: "#ff6700"},
{source: "91: principally", target: "91: corresponding", fill: "#ff6700"},
{source: "91: corresponding", target: "91: regulatory", fill: "#ff6700"},
{source: "91: testing manufacture", target: "97: Furthermore ", fill: "#195905"},
{source: "97: Furthermore ", target: "97: ordinary course", fill: "#195905"},
{source: "97: ordinary course", target: "97: must frequently", fill: "#195905"},
{source: "97: must frequently", target: "97: subjective judgments with respect", fill: "#195905"},
{source: "97: subjective judgments with respect", target: "97: compliance with applicable laws", fill: "#195905"},
{source: "97: compliance with applicable laws", target: "97: regulations", fill: "#195905"},
{source: "97: Furthermore ", target: "188: been approved by", fill: "#808080"},
{source: "188: been approved by", target: "188: Financial Accounting Standards Board ", fill: "#808080"},
{source: "188: Financial Accounting Standards Board ", target: "188: record compensation expense", fill: "#808080"},
{source: "188: record compensation expense", target: "188: operations", fill: "#808080"},
{source: "188: operations", target: "188: equity compensation instruments", fill: "#808080"},
{source: "188: equity compensation instruments", target: "188: director stock options using", fill: "#808080"},
{source: "188: director stock options using", target: "188: fair value method", fill: "#808080"},
{source: "188: been approved by", target: "192: market price", fill: "#a32638"},
{source: "192: market price", target: "192: common stock", fill: "#a32638"},
{source: "192: common stock", target: "192: been highly volatile", fill: "#a32638"},
{source: "192: been highly volatile", target: "192: fluctuated substantially", fill: "#a32638"},
{source: "192: market price", target: "START_HERE", fill: "#a32638"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Home Improvement Retail</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Offer peace proposal</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pricing_strategies">Pricing strategies</a></td>
      <td>A business can use a variety of pricing strategies when selling a product or service. To determine the most effective pricing strategy for a company, senior executives need to first identify the company's pricing position, pricing segment, pricing capability and their competitive pricing reaction strategy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hartford_Distributors_shooting">Hartford Distributors shooting</a></td>
      <td>The Hartford Distributors shooting was a mass shooting that occurred on August 3, 2010, in Manchester, Connecticut, United States. The location of the crime was a warehouse owned by Hartford Distributors, a beer distribution company.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Quality_Distributors">Quality Distributors</a></td>
      <td>Quality Distributors FC are a professional association football (soccer) club in Guam. They play in the Guam Soccer League.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_film_distributors_by_country">List of film distributors by country</a></td>
      <td>This is a list of motion picture distributors, past and present, sorted alphabetically by country.\n\n\n== Albania ==\nConstantin Film\nUnited International Pictures\n\n\n== Argentina ==\nBuena Vista International\nWarner Bros.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sony_Pictures_Motion_Picture_Group">Sony Pictures Motion Picture Group</a></td>
      <td>Sony Pictures Entertainment Motion Picture Group (commonly known as Sony Pictures Motion Picture Group, formerly known as the Columbia TriStar Motion Picture Group until 2013, and abbreviated as SPMPG) is a division of Sony Pictures Entertainment to manage its motion picture operations. It was launched in 1998 by integrating the businesses of Columbia Pictures Industries, Inc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Risk_management">Risk management</a></td>
      <td>Risk management is the identification, evaluation, and prioritization of risks (defined in ISO 31000 as the effect of uncertainty on objectives) followed by coordinated and economical application of resources to minimize, monitor, and control the probability or impact of unfortunate events or to maximize the realization of opportunities.\nRisks can come from various sources including uncertainty in international markets, threats from project failures (at any phase in design, development, production, or sustaining of life-cycles), legal liabilities, credit risk, accidents, natural causes and disasters, deliberate attack from an adversary, or events of uncertain or unpredictable root-cause.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Assets_under_management">Assets under management</a></td>
      <td>In finance, assets under management (AUM), sometimes called funds under management, measures the total market value of all the financial assets which an individual or financial institution—such as a mutual fund, venture capital firm, or depository institution—or a decentralized network protocol controls, typically on behalf of a client.  These funds may be managed for clients/users or for themselves in the case of a financial institution which has mutual funds or holds its own venture capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Defence_mechanism">Defence mechanism</a></td>
      <td>In psychoanalytic theory, a defence mechanism (American English: defense mechanism), is an unconscious psychological operation that functions to protect a person from anxiety-producing thoughts and feelings related to internal conflicts and outer stressors.Defence mechanisms may result in healthy or unhealthy consequences depending on the circumstances and frequency with which the mechanism is used. Defence mechanisms (German: Abwehrmechanismen) are psychological strategies brought into play by the unconscious mind to manipulate, deny, or distort reality in order to defend against feelings of anxiety and unacceptable impulses and to maintain one's self-schema or other schemas.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Day_the_Music_Died">The Day the Music Died</a></td>
      <td>On February 3, 1959, American rock and roll musicians Buddy Holly, Ritchie Valens, and "The Big Bopper" J. P. Richardson were killed in a plane crash near Clear Lake, Iowa, together with pilot Roger Peterson. The event later became known as "The Day the Music Died" after singer-songwriter Don McLean referred to it as such in his 1971 song "American Pie".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/North_American_Free_Trade_Agreement">North American Free Trade Agreement</a></td>
      <td>The North American Free Trade Agreement (NAFTA ; Spanish: Tratado de Libre Comercio de América del Norte, TLCAN; French: Accord de libre-échange nord-américain, ALÉNA) was an agreement signed by Canada, Mexico, and the United States that created a trilateral trade bloc in North America. The agreement came into force on January 1, 1994, and superseded the 1988 Canada–United States Free Trade Agreement between the United States and Canada.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Formula_One_regulations">Formula One regulations</a></td>
      <td>The numerous Formula One regulations, made and enforced by the FIA and later the FISA, have changed dramatically since the first Formula One World Championship in 1950. This article covers the current state of F1 technical and sporting regulations, as well as the history of the technical regulations since 1950.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Radio_regulation">Radio regulation</a></td>
      <td>Radio regulation refers to the regulation and licensing of radio in international law, by individual governments, and by municipalities.\n\n\n== International regulation ==\nThe International Telecommunication Union (ITU) is a specialized agency of the United Nations (UN) that is responsible for issues that concern information and communication technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation_of_therapeutic_goods">Regulation of therapeutic goods</a></td>
      <td>The regulation of therapeutic goods, defined as drugs and therapeutic devices, varies by jurisdiction. In some countries, such as the United States, they are regulated at the national level by a single agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Codes,_Rules_and_Regulations">New York Codes, Rules and Regulations</a></td>
      <td>The New York Codes, Rules and Regulations (NYCRR) contains New York state rules and regulations. The NYCRR is officially compiled by the New York State Department of State's Division of Administrative Rules.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>QUIDEL CORP /DE/      Item 1A     Risk Factors                           Risks Related to Our Business       Our operating results <font color="blue">may fluctuate <font color="blue">adversely</font> as</font> a result of many factors     that are outside our control</td>
    </tr>
    <tr>
      <td><font color="blue">Fluctuations </font>in our operating results, for any reason, could cause our     growth or operating results to fall below the <font color="blue">expectations</font> of investors and     securities  analysts</td>
    </tr>
    <tr>
      <td>For the year ended <font color="blue">December </font>31, 2005, net sales     increased  17prca  to dlra88dtta7 million from dlra76dtta1 million for the year ended     <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>For further discussion of this increase, refer to Item 7</td>
    </tr>
    <tr>
      <td>“Management’s Discussion and Analysis of Financial Condition and Results of     Operation” included in this <font color="blue">Annual Report</font></td>
    </tr>
    <tr>
      <td>Our sales estimates for <font color="blue"><font color="blue">future period</font>s</font> are <font color="blue">based on</font> estimated end-user     demand for our products</td>
    </tr>
    <tr>
      <td>Sales to our <font color="blue">distribution</font> partners would fall short     of <font color="blue">expectations</font> if <font color="blue">distributor</font> <font color="blue">inventories</font> increase because of less than     estimated end-user <font color="blue">consumption</font></td>
    </tr>
    <tr>
      <td>Other  factors  that  are beyond our control and that <font color="blue">could affect</font> our     operating results in the future include:       ·       <font color="blue">seasonal <font color="blue">fluctuations</font></font> in our sales of <font color="blue">Group A Strep </font>and influenza     tests, which are <font color="blue">generally</font> highest in fall and winter, thus resulting in     <font color="blue">generally</font> lower operating results in the second and <font color="blue">third calendar quarters</font>     and higher operating results in the first and <font color="blue">fourth calendar quarters</font>;       ·        timing of onset, the length, and severity of the cold and flu     seasons;       ·       <font color="blue">recent media attention focused on</font> a <font color="blue">potential influenza pandemic</font> and     the  related potential impact on humans from avian flu, as well as the     <font color="blue"><font color="blue">uncertainty</font> surrounding</font> the <font color="blue">detection</font> of H5N1 in human specimens;       ·       changes in the level of competition, such as would occur if one of     our larger and <font color="blue">better financed <font color="blue">competitors</font> introduced</font> a new or lower priced     product to <font color="blue"><font color="blue">compete with</font> one</font> of our products;       ·       changes in <font color="blue">economic <font color="blue">conditions</font></font> in our domestic and <font color="blue">international</font>     markets, such as economic downturns, reduced consumer demand, inflation and     <font color="blue">currency <font color="blue">fluctuations</font></font>;       ·       changes in sales levels, since a <font color="blue">significant</font> portion of our costs     are fixed <font color="blue">costs with</font> the result that <font color="blue"><font color="blue">relatively</font> higher <font color="blue">sales could</font> likely</font>     increase <font color="blue">profitability</font> but <font color="blue">relatively</font> lower sales would not <font color="blue">reduce costs by</font>     the <font color="blue">same proportion</font>, and <font color="blue">hence could</font> cause operating losses;       ·       lower than anticipated <font color="blue">market penetration</font> of our <font color="blue">new products</font>;       ·        <font color="blue">significant</font>  quantities  of  our product in our <font color="blue">distributor</font>s’     <font color="blue">inventories</font> or <font color="blue">distribution</font> channels; and       ·       changes in <font color="blue">distributor</font> buying patterns</td>
    </tr>
    <tr>
      <td>We are involved in pending, and <font color="blue">may become involved</font> in future, <font color="blue">intellectual</font>     property  <font color="blue">infringement</font>  disputes,  which are costly and <font color="blue">could limit</font> or     eliminate our ability to use certain of our <font color="blue">core <font color="blue">technologies</font></font> in the future     and sell our products</td>
    </tr>
    <tr>
      <td>As <font color="blue">previously</font> disclosed, beginning in <font color="blue">February </font>2004, a number of legal     <font color="blue">proceedings</font> were initiated by us and/or <font color="blue">Inverness Medical Innovations Inc</font></td>
    </tr>
    <tr>
      <td>(“IMA”) and/or their <font color="blue">affiliates</font> in <font color="blue">Germany and the US </font>raising, among other     items, issues of patent <font color="blue">infringement</font>, patent enforceability and patent     <font color="blue">invalidity</font>  relative to fundamental, lateral-flow <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In legal     <font color="blue">proceedings</font>  in  the  US,  in addition to IMA, Applied Biotech, Inc</td>
    </tr>
    <tr>
      <td>(“Applied”), Armkel LLC (now “Church &amp; Dwight”), Wampole Laboratories LLC     (“Wampole”), Inverness Medical Switzerland GmbH (“IMA Switzerland”) and     Unipath Diagnostics GmbH (“Unipath”) were <font color="blue">parties <font color="blue">also involved</font></font> in the legal     proceeding</td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________       In April 2005, we <font color="blue">entered into</font> an <font color="blue"><font color="blue">agreement</font> with</font> IMA settling all domestic     and <font color="blue">international</font> actions involving us, IMA, and IMA’s <font color="blue">affiliates</font> (Applied,     Wampole, IMA Switzerland and Unipath)</td>
    </tr>
    <tr>
      <td>Under the terms of the settlement     <font color="blue">agreement</font>, we and IMA agreed to cross-license, and to cause their <font color="blue">affiliates</font>     to cross-license, the parties’ respective <font color="blue">lateral flow</font> patent portfolios and     to  dismiss,  and  to  cause their <font color="blue">affiliates</font> to dismiss, the parties’     <font color="blue">respective cases</font></td>
    </tr>
    <tr>
      <td>We agreed to make a <font color="blue">net payment</font> to IMA of dlra17dtta0 million     and to <font color="blue">pay net royalties</font> of 8dtta5prca on future sales of our <font color="blue">current <font color="blue">lateral flow</font></font>     products and future <font color="blue">lateral flow</font> products that utilize or incorporate any     <font color="blue">inventions</font> claimed in the valid and enforceable claims of IMA <font color="blue">lateral flow</font>     patents</td>
    </tr>
    <tr>
      <td>Our <font color="blue">declaratory relief action against</font> Church &amp; Dwight has not <font color="blue">been settled</font>,     nor has Church &amp; Dwight’s claim for patent <font color="blue">infringement</font>, which seeks damages     against  us  for  over-the-counter sales and <font color="blue">preliminary</font> and permanent     <font color="blue">injunctions</font> in the over-the-counter market</td>
    </tr>
    <tr>
      <td>There is not a <font color="blue">specific amount</font> or <font color="blue">range sought</font> in damages in the Church &amp;     Dwight <font color="blue">lawsuit discussed</font> above</td>
    </tr>
    <tr>
      <td>Given the early stage of the action, we     cannot  predict the <font color="blue">ultimate outcome</font> of this matter at this time</td>
    </tr>
    <tr>
      <td>As a     result, in <font color="blue">accordance</font> with SFAS Nodtta 5 “Accounting for Contingencies”, we     have  disclosed the existence of this lawsuit; however, no accrual for     <font color="blue">potential losses</font>, if any, has <font color="blue">been recorded</font></td>
    </tr>
    <tr>
      <td>Additionally, one other <font color="blue">industry participant</font> has <font color="blue">sent us correspondence</font>     requesting that we obtain a license to patents for which it has alleged     <font color="blue"><font color="blue">enforcement</font> rights</font></td>
    </tr>
    <tr>
      <td>We are continuing to assess the <font color="blue">relevant <font color="blue">intellectual</font></font>     property in light of our own business strategies and the costs and risks     <font color="blue">associated with defending</font> our position</td>
    </tr>
    <tr>
      <td>In this regard, we continue to     evaluate the license request, which may result in our payment of royalties     under royalty-bearing licenses in a <font color="blue">future period</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">royalty payments</font>     could result in a material increase in our <font color="blue">product costs</font> and have a material     adverse effect on our profits</td>
    </tr>
    <tr>
      <td>Further, no assurance can be given that we     would be able to obtain any license to third-party <font color="blue">intellectual</font> property     under <font color="blue">commercially</font> reasonable terms, if at all</td>
    </tr>
    <tr>
      <td>We are <font color="blue">also involved</font> in other <font color="blue"><font color="blue">litigation</font> matters from</font> time to time in the     <font color="blue">ordinary course</font> of business</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>believes that any and all such other     actions, in the aggregate, will not have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We     also maintain insurance, including coverage for <font color="blue">product <font color="blue">liability</font></font> claims, in     amounts  <font color="blue">which <font color="blue">management</font></font> believes <font color="blue">appropriate given</font> the nature of our     business</td>
    </tr>
    <tr>
      <td>As a more general matter, our involvement in <font color="blue">litigation</font>, as may arise from     time to time, to determine rights in <font color="blue">proprietary</font> <font color="blue">technology</font> could <font color="blue">adversely</font>     affect our net sales and business because:       ·       the pendency of any <font color="blue">litigation</font> may of itself cause our <font color="blue">distributor</font>s     to <font color="blue">reduce purchases</font> of our products;       ·       it <font color="blue">may consume</font> a substantial portion of managerial and financial     resources;       ·       its <font color="blue">outcome would</font> be uncertain and a <font color="blue">court may find</font> the third-party     patent claims valid and <font color="blue">infringed by</font> our products;       ·       an <font color="blue">adverse outcome could</font> subject us to <font color="blue">significant</font> <font color="blue">liability</font> in the     form of past <font color="blue">royalty payments</font>, penalties, special and <font color="blue">punitive damages</font>,     and/or future <font color="blue">royalty payments</font> <font color="blue">significant</font>ly <font color="blue">affecting</font> our <font color="blue">future earnings</font>;       ·       failure to obtain a <font color="blue">necessary license upon</font> an <font color="blue">adverse outcome could</font>     prevent  <font color="blue">us from selling</font> our current products or other products we may     develop; and       ·       a <font color="blue">court could award</font> a <font color="blue">preliminary</font> and/or permanent injunction which     would prevent <font color="blue">us from selling</font> our current or <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>18     ______________________________________________________________________       To <font color="blue">remain <font color="blue">competitive</font></font>, we <font color="blue">must continue</font> to develop or obtain <font color="blue">proprietary</font>     <font color="blue">technology</font> rights; otherwise, other <font color="blue">companies may increase</font> their market     share <font color="blue">by selling products</font> that <font color="blue">compete with</font> our products</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitive</font> position</font> is <font color="blue">heavily dependent on</font> obtaining and protecting     our  own <font color="blue">proprietary</font> <font color="blue">technology</font> or obtaining <font color="blue">licenses from others</font></td>
    </tr>
    <tr>
      <td>Our     ability  to  compete  <font color="blue">successfully</font> in the <font color="blue"><font color="blue">diagnostic</font> market depends on</font>     <font color="blue">continued <font color="blue">development</font></font> and <font color="blue">introduction</font> of new <font color="blue">proprietary</font> <font color="blue">technology</font> and the     <font color="blue">improvement</font> of existing <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot continue</font> to obtain and     protect <font color="blue">proprietary</font> <font color="blue">technology</font>, our net sales and gross <font color="blue">profits could</font> be     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Moreover, our current and <font color="blue">future licenses may</font> not be     adequate for the operation of our business</td>
    </tr>
    <tr>
      <td>We have <font color="blue">issued patents both</font> in the US and <font color="blue">international</font>ly, with     expiration  dates ranging from the present through <font color="blue">approximately</font> 2022</td>
    </tr>
    <tr>
      <td>Additionally, we have <font color="blue">patent <font color="blue">application</font>s pending throughout</font> the world</td>
    </tr>
    <tr>
      <td>These <font color="blue">pending patent <font color="blue">application</font>s may</font> not result in the issuance of any     patents, or if issued, may not have priority over others’ <font color="blue">application</font>s or     may  not <font color="blue">offer protection against <font color="blue">competitors</font> with</font> similar <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Moreover,  any  <font color="blue">patents issued</font> to us may be challenged, invalidated or     <font color="blue">circumvented</font> in the future</td>
    </tr>
    <tr>
      <td>In addition to the US, we have <font color="blue">patents issued</font>     in various other countries including, for example, Australia, Canada, Japan     and various European countries, including, France, Germany, Italy, Spain and     <font color="blue">the United Kingdom</font></td>
    </tr>
    <tr>
      <td>Third parties can make, use and <font color="blue">sell products <font color="blue">covered by</font></font>     our patents in any country in which we do not have <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue">also license</font> the right to use our products to our <font color="blue">customers under label</font>     licenses  that are for <font color="blue">research purposes only</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">licenses could</font> be     contested and, because we <font color="blue">cannot monitor</font> all <font color="blue">potential <font color="blue">unauthorized use</font>s</font> of     our <font color="blue">products around</font> the world, we might not be aware of an <font color="blue">unauthorized use</font>     and  might  not  be  able  to  enforce  the  <font color="blue">license restrictions</font> in a     cost-<font color="blue">effective</font> manner</td>
    </tr>
    <tr>
      <td>Also, we may not be able to obtain licenses for     <font color="blue">technology</font>  <font color="blue">patented by others</font> and required to produce our <font color="blue">products on</font>     <font color="blue">commercially</font> reasonable terms</td>
    </tr>
    <tr>
      <td>In order to <font color="blue">remain <font color="blue">competitive</font></font> and profitable, we must expend considerable     resources  to  <font color="blue">introduce new <font color="blue">technologies</font></font> and products and develop new     markets</td>
    </tr>
    <tr>
      <td>Our  failure to <font color="blue">successfully</font> <font color="blue">introduce new <font color="blue">technologies</font></font>, new     products and develop <font color="blue"><font color="blue">new markets</font> could</font> have a material adverse effect on our     business and prospects</td>
    </tr>
    <tr>
      <td>We devote a <font color="blue">significant</font> amount of <font color="blue">financial resources</font> to <font color="blue">researching</font> and     developing new <font color="blue">technologies</font>, <font color="blue">new products</font> and <font color="blue">new markets</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font>,     <font color="blue">manufacture</font> and sale of <font color="blue"><font color="blue">diagnostic</font> products</font> require a <font color="blue">significant</font> <font color="blue">investment</font>     of resources</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">no assurances</font> can be given that our efforts to     develop new <font color="blue">technologies</font> or products will be successful, including, without     <font color="blue">limitation</font>,  our <font color="blue">strategic efforts</font> relating to: (i) our LTF <font color="blue">technology</font>     platform and migration of products to that platform and (ii) identifying and     <font color="blue">commercializing new markers</font> and products in oncology and <font color="blue">bone health</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">development</font>  of  <font color="blue">new markets</font> also requires a substantial <font color="blue">investment</font> of     resources, such as new employees, offices and <font color="blue"><font color="blue">manufacturing</font> facilities</font></td>
    </tr>
    <tr>
      <td>Accordingly, we are likely to <font color="blue">incur increased</font> operating <font color="blue">expenses as</font> a result     of our increased <font color="blue">investment</font> in sales and marketing <font color="blue">activities</font>, <font color="blue">manufacturing</font>     scale-up and new product <font color="blue">development</font> associated with our efforts to:       ·  provide clinicians with validated, value-based proof which encompasses     the <font color="blue">clinical efficacy</font> and <font color="blue">economic efficiency</font> of our rapid POC tests for the     <font color="blue">professional market</font>;       ·   strengthen  market  and brand <font color="blue">leadership</font> in <font color="blue">infectious disease</font> and     <font color="blue">reproductive health</font>;       ·  drive growth by establishing dedicated <font color="blue">distributor</font> partnerships;       ·  <font color="blue">drive profit through further refinement</font> of <font color="blue">industry leading <font color="blue">manufacturing</font></font>     <font color="blue">efficiencies</font>;       ·  identify and commercialize new markers, products and <font color="blue">collaborations</font> in     oncology and <font color="blue">bone health</font> through our SPG;       19     ______________________________________________________________________       ·  complete the full-scale manufacturability feasibility study for our LTF     <font color="blue">immunoassay</font> and <font color="blue">continue parallel pathways</font> for <font color="blue">development</font> and <font color="blue">acquisition</font>     of other <font color="blue">qualitative</font> and quantitative <font color="blue">technology</font> platforms;       ·  develop and maintain <font color="blue">key <font color="blue">relationships</font> with third parties</font> and <font color="blue">cooperative</font>     <font color="blue">collaborations</font>; and       ·  aggressively pursue licensing, <font color="blue">acquisition</font> and <font color="blue">partnership opportunities</font>     that meet our <font color="blue">dedicated focus on</font> <font color="blue">Research to Rapids</font></td>
    </tr>
    <tr>
      <td>As a result of any number of <font color="blue">risk factors</font> identified in this <font color="blue">Annual Report</font>,     no assurance can be given that we will be successful in <font color="blue">implementing</font> our     operational, growth and other <font color="blue">strategic efforts</font></td>
    </tr>
    <tr>
      <td>In addition, the funds for     the foregoing projects have in the <font color="blue">past come primarily from</font> our business     <font color="blue">operations</font> and a working <font color="blue">capital line</font> of credit</td>
    </tr>
    <tr>
      <td>If our business slows and     we <font color="blue">become less profitable</font>, and as a result have <font color="blue">less money available</font> to fund     research and <font color="blue">development</font>, we will have to <font color="blue">decide at</font> that time <font color="blue">which programs</font>     to  cut, and by how much</td>
    </tr>
    <tr>
      <td>Similarly, if adequate financial, personnel,     equipment or other resources are not available, we may be required to delay     or  scale back our <font color="blue">strategic efforts</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">operations</font> will be <font color="blue">adversely</font>     affected if our net sales and gross profits do not <font color="blue"><font color="blue">corresponding</font>ly increase</font>     or  if  our product and market <font color="blue">development</font> efforts are <font color="blue">unsuccessful</font> or     delayed</td>
    </tr>
    <tr>
      <td>Furthermore, our failure to <font color="blue">successfully</font> introduce <font color="blue">new products</font> and     develop <font color="blue"><font color="blue">new markets</font> could</font> have a material adverse effect on our business and     prospects</td>
    </tr>
    <tr>
      <td>We  rely  on  a limited number of key <font color="blue">distributor</font>s which account for a     substantial majority of our net sales</td>
    </tr>
    <tr>
      <td>The loss of any key <font color="blue">distributor</font> or an     <font color="blue">unsuccessful</font>  effort to <font color="blue">directly distribute</font> our <font color="blue"><font color="blue">products could</font> lead</font> to     <font color="blue">reduced sales</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have  <font color="blue">distributor</font>  <font color="blue">relationships</font>  with  <font color="blue">approximately</font> 80     <font color="blue">distributor</font>s,  the  market  is  dominated  by  a  small group of these     <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>Four of our <font color="blue">distributor</font>s, which are considered to be among the     market leaders, <font color="blue">collectively</font> accounted for <font color="blue">approximately</font> 64prca, 56prca and 58prca of     our  net  sales  for the years ended <font color="blue">December </font>31, 2005, 2004 and 2003,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The loss or <font color="blue">termination</font> of our <font color="blue">relationship with</font> any of these     key <font color="blue">distributor</font>s could <font color="blue">significant</font>ly disrupt our business <font color="blue">unless suitable</font>     <font color="blue"><font color="blue">alternative</font>s</font> were <font color="blue">timely found</font> or lost sales to one <font color="blue">distributor</font> are absorbed     by another <font color="blue">distributor</font></td>
    </tr>
    <tr>
      <td>Finding a suitable <font color="blue">alternative</font> may pose <font color="blue">challenges</font>     in our industry’s <font color="blue">competitive</font> <font color="blue">environment</font>, and another suitable <font color="blue">distributor</font>     may not be found on satisfactory terms</td>
    </tr>
    <tr>
      <td>For instance, some <font color="blue">distributor</font>s     already have <font color="blue">exclusive arrangements with</font> our <font color="blue">competitors</font>, and others do not     have the same level of <font color="blue">penetration into</font> our <font color="blue">target markets as</font> our existing     <font color="blue">distributor</font>s</td>
    </tr>
    <tr>
      <td>If  net  sales to these or any of our other <font color="blue">significant</font>     <font color="blue">distributor</font>s were to decrease in any material amount in the future, our     business, operating results and <font color="blue"><font color="blue">financial condition</font> could</font> be <font color="blue">materially</font> and     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>As an <font color="blue">alternative</font>, we could expand our efforts to distribute and market our     products directly</td>
    </tr>
    <tr>
      <td>This <font color="blue">alternative</font>, however, would require substantial     <font color="blue">investment</font> in <font color="blue"><font color="blue">additional</font> sales</font> and <font color="blue">marketing resources</font>, including hiring     <font color="blue">additional</font> field sales personnel, which would <font color="blue">significant</font>ly increase our     future selling, general and <font color="blue"><font color="blue">administrative</font> expenses</font></td>
    </tr>
    <tr>
      <td>In addition, because we     do not have experience in direct <font color="blue">distribution</font> and marketing, our direct     <font color="blue">distribution</font>  efforts  may  not  be successful</td>
    </tr>
    <tr>
      <td>If we were to make the     substantial <font color="blue">investment</font> to <font color="blue">directly distribute</font> and market our products and     were  <font color="blue">unsuccessful</font>,  our net sales and <font color="blue">profits could</font> be <font color="blue">materially</font> and     <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>We may not achieve <font color="blue">market <font color="blue">acceptance</font></font> of our <font color="blue">products among physicians</font> and     other <font color="blue">healthcare providers</font>, and this would have a negative effect on future     <font color="blue">sales growth</font></td>
    </tr>
    <tr>
      <td>A large part of our business is <font color="blue">based on</font> the sale of rapid POC <font color="blue">diagnostic</font>     tests that physicians and other <font color="blue">healthcare providers</font> can <font color="blue">administer</font> in their     own <font color="blue">facilities without sending samples</font> to <font color="blue">laboratories</font></td>
    </tr>
    <tr>
      <td>Clinical reference     <font color="blue">laboratories</font> and hospital-based <font color="blue">laboratories</font> are <font color="blue">significant</font> <font color="blue">competitors</font> for     our  products  and  provide a majority of the <font color="blue">diagnostic</font> tests used by     physicians and other <font color="blue">healthcare providers</font></td>
    </tr>
    <tr>
      <td>Our future sales depend on, among     other matters, capture of <font color="blue">sales from</font> these <font color="blue">laboratories</font> by achieving market     <font color="blue">acceptance</font> of POC <font color="blue">testing from physicians</font> and other <font color="blue">healthcare providers</font></td>
    </tr>
    <tr>
      <td>If     we do not <font color="blue">capture sales at</font>       20     ______________________________________________________________________       the levels we have budgeted for, our <font color="blue">net sales will</font> not grow as much as we     hope and the costs we have <font color="blue">incurred will</font> be <font color="blue">disproportionate</font> to our sales     levels</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">clinical reference</font> and hospital-based <font color="blue">laboratories</font>     <font color="blue">will continue</font> to <font color="blue">compete vigorously against</font> our POC <font color="blue"><font color="blue">diagnostic</font> products</font> in     order  to  maintain and expand their <font color="blue">existing dominance</font> of the overall     <font color="blue">diagnostic</font> testing market</td>
    </tr>
    <tr>
      <td>Moreover, even if we can <font color="blue">demonstrate</font> that our     products  are  more  cost-<font color="blue">effective</font> or save time, physicians and other     healthcare  <font color="blue">providers may resist</font> changing to POC tests</td>
    </tr>
    <tr>
      <td>Our failure to     achieve <font color="blue">market <font color="blue">acceptance</font></font> from physicians and <font color="blue">healthcare providers</font> with     respect to the use of our POC <font color="blue"><font color="blue">diagnostic</font> products</font> would have a negative     effect on our future <font color="blue">sales growth</font></td>
    </tr>
    <tr>
      <td>Intense <font color="blue">competition with</font> other <font color="blue">manufacture</font>rs of POC <font color="blue"><font color="blue">diagnostic</font> products</font> may     reduce our sales</td>
    </tr>
    <tr>
      <td>In addition to competition from <font color="blue">laboratories</font>, our POC <font color="blue">diagnostic</font> tests     <font color="blue">compete with</font> similar products made by our <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31,     2005, our estimated US <font color="blue">professional market</font> share for our key POC products     was 66prca in influenza, 50prca for pregnancy and 46prca for <font color="blue">Group A Strep </font>tests</td>
    </tr>
    <tr>
      <td>There are, however, a large number of <font color="blue">multinational</font> and regional <font color="blue">competitors</font>     making <font color="blue">investment</font>s in competing <font color="blue">technologies</font> and products, including several     large <font color="blue">pharmaceutical</font> and <font color="blue">diversified healthcare companies</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">competitors</font>     include Beckman, Fisher, Wampole, Becton, Genzyme, IMA, Binax, Remel, and     Thermo</td>
    </tr>
    <tr>
      <td>We <font color="blue">also face competition from</font> our <font color="blue">distributor</font>s since some have     created, and <font color="blue">others may decide</font> to create, their own products to <font color="blue">compete with</font>     ours</td>
    </tr>
    <tr>
      <td>A number of our <font color="blue">competitors</font> have a potential <font color="blue">competitive</font> advantage     because they have substantially greater financial, technical, research and     other resources, and larger, more established marketing, sales, <font color="blue">distribution</font>     and <font color="blue">service <font color="blue">organizations</font> than</font> we have</td>
    </tr>
    <tr>
      <td>Moreover, some <font color="blue">competitors</font> offer     <font color="blue">broader product lines</font> and have <font color="blue">greater name recognition than</font> we have</td>
    </tr>
    <tr>
      <td>If our     <font color="blue">competitors</font>’ products are more <font color="blue"><font color="blue">effective</font> than ours</font> or acquire market share     from our <font color="blue">products through</font> more <font color="blue"><font color="blue">effective</font> marketing</font> or <font color="blue">competitive</font> pricing,     our  net sales and <font color="blue">profits could</font> be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>also has the effect of limiting the prices we can charge for our     products</td>
    </tr>
    <tr>
      <td>Our products are <font color="blue">highly regulated by various <font color="blue">governmental</font> agencies</font></td>
    </tr>
    <tr>
      <td>Any     changes  to the <font color="blue">existing laws</font> and <font color="blue">regulations</font> may <font color="blue">adversely</font> impact our     ability to <font color="blue">manufacture</font> and market our products</td>
    </tr>
    <tr>
      <td>The testing, <font color="blue">manufacture</font> and sale of our products are subject to regulation     <font color="blue">by numerous <font color="blue">governmental</font> <font color="blue">authorities</font></font> in the US, <font color="blue">principally</font> the FDA and     <font color="blue">corresponding</font> state and foreign <font color="blue">regulatory</font> agencies</td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">regulates most</font>     of our products, which are all <font color="blue">Class I or II </font>devices</td>
    </tr>
    <tr>
      <td><font color="blue">The US Department </font>of     <font color="blue">Agriculture  </font>regulates our <font color="blue">veterinary products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future performance</font>     depends on, among other matters, our estimates as to when and at what cost     we will receive <font color="blue">regulatory</font> approval for <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font>approval     can be a lengthy, expensive and <font color="blue">uncertain process</font>, making the timing and     costs of <font color="blue">approvals <font color="blue">difficult</font></font> to predict</td>
    </tr>
    <tr>
      <td>Our <font color="blue">net sales would</font> be <font color="blue">negatively</font>     <font color="blue">affected by delays</font> in the receipt of, or failure to receive, approvals or     <font color="blue">clearances</font>, the loss of <font color="blue">previously</font> received approvals or <font color="blue">clearances</font> or the     placement of <font color="blue">limits on</font> the marketing and use of our products</td>
    </tr>
    <tr>
      <td>Furthermore, in the <font color="blue">ordinary course</font> of business, we <font color="blue">must frequently</font> make     <font color="blue">subjective judgments with respect</font> to <font color="blue"><font color="blue">compliance with</font> applicable laws</font> and     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">regulators subsequently disagree with</font> the manner in which we     have sought to <font color="blue">comply with</font> these <font color="blue">regulations</font>, we could be subjected to     substantial civil and criminal penalties, as well as product recall, seizure     or <font color="blue">injunction with respect</font> to the sale of our products</td>
    </tr>
    <tr>
      <td>The <font color="blue">assessment</font> of     any  civil and <font color="blue">criminal penalties <font color="blue">against us</font> could severely impair</font> our     reputation  within  the  industry and any <font color="blue">limitation</font> on our ability to     <font color="blue">manufacture</font> and market our <font color="blue">products could</font> have a material adverse effect on     our business</td>
    </tr>
    <tr>
      <td>We  are  subject to numerous government <font color="blue">regulations</font> in addition to FDA     regulation, and <font color="blue">compliance with</font> changes <font color="blue">could increase</font> our costs</td>
    </tr>
    <tr>
      <td>In addition to FDA and other <font color="blue">regulations</font> described <font color="blue">previously</font>, numerous laws     relating  to  such  matters  as safe working <font color="blue">conditions</font>, <font color="blue">manufacturing</font>     practices, <font color="blue">environment</font>al protection, fire hazard control and disposal of     <font color="blue">hazardous</font>  or  <font color="blue">potentially</font>  <font color="blue">hazardous</font>  substances  impact our business     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If these       21     ______________________________________________________________________       laws change or <font color="blue">laws regulating</font> any of our <font color="blue">businesses</font> are added, the costs of     compliance  with  these  laws  <font color="blue">could substantially increase</font> our costs</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with any <font color="blue">future modifications</font> of these laws or <font color="blue">laws regulating</font>     the <font color="blue">manufacture</font> and marketing of our <font color="blue">products could</font> result in substantial     costs and loss of sales or customers</td>
    </tr>
    <tr>
      <td>Because of the number and extent of     the  laws  and  <font color="blue">regulations</font>  <font color="blue">affecting</font> our industry, and the number of     <font color="blue">governmental</font> agencies whose actions <font color="blue">could affect</font> our <font color="blue">operations</font>, it is     impossible  to  reliably  predict the full nature and impact of future     <font color="blue">legislation</font> or <font color="blue">regulatory</font> <font color="blue">development</font>s relating to our industry</td>
    </tr>
    <tr>
      <td>To the     extent the costs and procedures associated with meeting new <font color="blue">requirements</font> are     substantial, our business and results of <font color="blue">operations</font> could be <font color="blue">adversely</font>     affected</td>
    </tr>
    <tr>
      <td>We use <font color="blue">hazardous</font> materials in our business that may result in unexpected and     substantial claims <font color="blue">against us</font> relating to handling, storage or disposal</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> and <font color="blue"><font color="blue">manufacturing</font> <font color="blue">activities</font> involve</font> the     controlled  use  of  <font color="blue">hazardous</font> materials, including but not limited to     <font color="blue">chemicals</font> and biological materials such as dimethyl sulfate, sodium nitrite,     acetaldehyde, acrylamide, potassium bromate and <font color="blue">radionuclides</font></td>
    </tr>
    <tr>
      <td>Federal,     state and <font color="blue">local laws</font> and <font color="blue">regulations</font> govern the use, <font color="blue">manufacture</font>, storage,     handling and disposal of <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> include     <font color="blue">federal statutes popularly known as</font> CERCLA, RCRA and the Clean Water Act</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with these laws and <font color="blue">regulations</font> is <font color="blue">already expensive</font></td>
    </tr>
    <tr>
      <td>If any     <font color="blue">governmental</font>  <font color="blue">authorities</font> were to impose new <font color="blue">environment</font>al <font color="blue">regulations</font>     requiring compliance in addition to that required by existing <font color="blue">regulations</font>,     these  future  <font color="blue">environment</font>al  <font color="blue">regulations</font>  could  impair our research,     <font color="blue">development</font> or production efforts by imposing <font color="blue">additional</font>, and possibly     substantial, costs on our business</td>
    </tr>
    <tr>
      <td>In addition, because of the nature of     the <font color="blue">penalties provided</font> for in some of these <font color="blue">environment</font>al <font color="blue">regulations</font>, we     could be required to pay sizeable fines, penalties or damages in the event     of non<font color="blue">compliance with</font> <font color="blue">environment</font>al laws</td>
    </tr>
    <tr>
      <td>Any <font color="blue">environment</font>al violation or     <font color="blue">remediation requirement could also partially</font> or <font color="blue"><font color="blue">completely</font> shut down</font> our     research and <font color="blue"><font color="blue">manufacturing</font> facilities</font> and <font color="blue">operations</font>, which would have a     material  adverse  effect  on  our  business</td>
    </tr>
    <tr>
      <td>The  risk of <font color="blue">accidental</font>     <font color="blue">contamination</font> or <font color="blue">injury from</font> these <font color="blue">hazardous</font> materials cannot be <font color="blue">completely</font>     eliminated and exposure of <font color="blue">individuals</font> to these <font color="blue">materials could</font> result in     substantial fines, penalties or <font color="blue">damages as well</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">net <font color="blue">sales could</font></font> be affected by third-party <font color="blue">reimbursement</font> policies and     <font color="blue">potential cost constraints</font></td>
    </tr>
    <tr>
      <td>The end-users of our products are <font color="blue">primarily physicians</font> and other healthcare     providers</td>
    </tr>
    <tr>
      <td>Use of our products would be <font color="blue">adversely</font> impacted if physicians do     not receive adequate <font color="blue">reimbursement</font> for the cost of our <font color="blue">products by</font> their     patients’  healthcare  insurers or payors</td>
    </tr>
    <tr>
      <td>Our <font color="blue">net <font color="blue">sales could</font></font> also be     <font color="blue">adversely</font> affected by changes or trends in <font color="blue">reimbursement</font> policies of these     <font color="blue">governmental</font> or <font color="blue">private healthcare payors</font></td>
    </tr>
    <tr>
      <td>In the US, <font color="blue">healthcare providers</font>     <font color="blue">such as hospitals</font> and physicians who purchase <font color="blue"><font color="blue">diagnostic</font> products</font> <font color="blue">generally</font>     rely on third-party payors, <font color="blue">principally</font> private health insurance plans,     federal Medicare and state Medicaid, to reimburse all or part of the cost of     the  procedure</td>
    </tr>
    <tr>
      <td>We believe that the <font color="blue">overall escalating cost</font> of medical     products and services has led to, and <font color="blue">will continue</font> to lead to, increased     <font color="blue">pressures on</font> the healthcare industry, both foreign and domestic, to reduce     the cost of products and services</td>
    </tr>
    <tr>
      <td>Given the efforts to control and reduce     healthcare costs in the US in recent years, currently available levels of     <font color="blue">reimbursement</font>  may  not continue to be available in the future for our     <font color="blue">existing products</font> or products under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Third-party <font color="blue">reimbursement</font>     and <font color="blue">coverage may</font> not be available or adequate in either US or foreign     markets, current <font color="blue">reimbursement</font> amounts may be decreased in the future and     future <font color="blue">legislation</font>, regulation or <font color="blue">reimbursement</font> policies of third-party     payors  may reduce the demand for our products or <font color="blue">adversely</font> impact our     ability to sell our <font color="blue">products on</font> a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unexpected </font>increases in demand for our <font color="blue">products could</font> require us to spend     considerable resources to meet the demand or harm our customer <font color="blue">relationships</font>     if we are unable to meet demand</td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">unexpected increases</font> in the demand for our products, we may     be required to expend <font color="blue">additional</font> capital resources to meet these demands</td>
    </tr>
    <tr>
      <td>These <font color="blue">capital resources could involve</font> the cost of <font color="blue">new machinery</font> or even the     cost of new <font color="blue"><font color="blue">manufacturing</font> facilities</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">would increase</font> our <font color="blue">capital costs</font>,     which       22     ______________________________________________________________________       could <font color="blue">adversely</font> affect our earnings and <font color="blue">cash resources</font></td>
    </tr>
    <tr>
      <td>If we are unable to     develop <font color="blue">necessary <font color="blue">manufacturing</font> capabilities</font> in a <font color="blue">timely manner</font>, our net     <font color="blue">sales could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Failure to cost-<font color="blue">effective</font>ly increase     production  volumes,  if required, or lower than anticipated yields or     production problems <font color="blue">encountered</font> as a result of changes that we may make in     our  <font color="blue">manufacturing</font> processes to meet increased demand, could result in     shipment delays as well as increased <font color="blue">manufacturing</font> costs, which could also     have a material adverse effect on our net sales and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unexpected </font>increases in demand for our <font color="blue">products could</font> also require us to     obtain <font color="blue">additional</font> <font color="blue">raw materials</font> in order to <font color="blue">manufacture</font> products to meet the     demand</td>
    </tr>
    <tr>
      <td>Some <font color="blue">raw materials</font> require <font color="blue">significant</font> ordering lead time and some     are currently obtained from a <font color="blue">sole supplier</font> or a limited group of suppliers</td>
    </tr>
    <tr>
      <td>We have long-term supply <font color="blue">agreement</font>s with many of these suppliers, but these     long-term <font color="blue">agreement</font>s involve risks for us, such as our <font color="blue">potential <font color="blue">inability</font></font>     to obtain an <font color="blue">adequate supply</font> of <font color="blue">raw materials</font> and <font color="blue">components</font> and our reduced     control over pricing, quality and <font color="blue">timely delivery</font></td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that     one or more of these <font color="blue">suppliers may become unwilling</font> or unable to deliver     materials  to  us</td>
    </tr>
    <tr>
      <td>Any  shortfall  in our supply of <font color="blue">raw materials</font> and     <font color="blue">components</font>, and our <font color="blue">inability</font> to obtain <font color="blue">alternative</font> sources for this supply,     could have a material adverse effect on our net sales or cost of sales and     related profits</td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">meet customer demand</font> for our products, whether as a result     of <font color="blue">manufacturing</font> problems or supply shortfalls, could harm our customer     <font color="blue">relationships</font> and impair our <font color="blue">reputation within</font> the industry</td>
    </tr>
    <tr>
      <td>If one or more of our <font color="blue">products proves</font> to be defective, we could be subject     to claims of <font color="blue">liability</font> that could <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>A defect in the design or <font color="blue">manufacture</font> of our <font color="blue">products could</font> have a material     adverse effect on our reputation in the industry and subject us to claims of     <font color="blue">liability</font> for injuries and otherwise</td>
    </tr>
    <tr>
      <td>Any substantial <font color="blue">underinsured loss</font>     resulting from such a claim would have a material adverse effect on our     <font color="blue">profitability</font> and the damage to our reputation in the <font color="blue">industry could</font> have a     material adverse effect on our business</td>
    </tr>
    <tr>
      <td>We are exposed to business risk which, if not <font color="blue">covered by</font> insurance, could     have an adverse effect on our profits</td>
    </tr>
    <tr>
      <td><font color="blue">Claims  </font>may be made <font color="blue">against us</font> for types of damages, or for amounts of     damages, that are not <font color="blue">covered by</font> our insurance</td>
    </tr>
    <tr>
      <td>For example, although we     currently carry <font color="blue">product <font color="blue">liability</font></font> insurance for <font color="blue">liability</font> losses, there is a     risk that <font color="blue">product <font color="blue">liability</font></font> or other claims may exceed the amount of our     <font color="blue">insurance coverage</font> or may be <font color="blue">excluded from coverage under</font> the terms of our     policy</td>
    </tr>
    <tr>
      <td>Also, if we are held liable, our <font color="blue">existing insurance may</font> not be     <font color="blue">renewed at</font> the same cost and level of <font color="blue">coverage as currently</font> in effect, or     may not be <font color="blue">renewed at</font> all</td>
    </tr>
    <tr>
      <td>If we are held liable for a claim <font color="blue">against which</font>     we are not insured or for <font color="blue">damages exceeding</font> the limits of our insurance     coverage, whether arising out of <font color="blue">product <font color="blue">liability</font></font> matters or from some     other matter, that claim could have a material adverse effect on our results     of <font color="blue">operations</font> and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If  we are not able to manage our <font color="blue">growth strategy</font> and if we experience     <font color="blue"><font color="blue"><font color="blue">difficult</font>ies integrating</font> companies</font> or <font color="blue">technologies</font> we may acquire after the     <font color="blue">acquisition</font>, our <font color="blue">earnings may</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Our business strategy contemplates further growth in the scope of operating     and <font color="blue">financial systems</font> and the area of our <font color="blue">operations</font>, including further     expansion  outside  the  US,  as  new  products  are  developed  and     <font color="blue">commercialized</font></td>
    </tr>
    <tr>
      <td>We  may  experience  <font color="blue"><font color="blue">difficult</font>ies integrating</font> our own     <font color="blue">operations</font> with those of companies or <font color="blue">technologies</font> that we may acquire, and     as a result we may not realize our anticipated benefits and <font color="blue">cost savings</font>     within our expected time frame, or at all</td>
    </tr>
    <tr>
      <td>Because we have a <font color="blue">relatively</font>     small executive staff, future growth may also divert <font color="blue">management</font>’s attention     from other aspects of our business, and will place a strain on existing     <font color="blue">management</font>  and  our operational, financial and <font color="blue">management</font> information     systems</td>
    </tr>
    <tr>
      <td>Furthermore, we <font color="blue"><font color="blue">may expand into</font> markets</font> in which we have less     experience  or <font color="blue">incur <font color="blue">higher costs</font></font></td>
    </tr>
    <tr>
      <td>Should we <font color="blue">encounter <font color="blue">difficult</font>ies</font> in     managing these tasks, our <font color="blue">growth strategy</font> may suffer and our net sales and     gross <font color="blue">profits could</font> be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>23     ______________________________________________________________________       Our business could be <font color="blue">negatively</font> affected by the loss of or the <font color="blue">inability</font> to     <font color="blue">hire <font color="blue">key personnel</font></font></td>
    </tr>
    <tr>
      <td>Our  future  success  depends in part on our ability to retain our key     technical, sales, marketing and <font color="blue">executive personnel</font> and our ability to     identify and hire <font color="blue">additional</font> qualified personnel</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for these     personnel is intense, both in the industry in which we operate and also in     San Diego and Santa Clara where our <font color="blue">headquarters</font> and the majority of our     <font color="blue">operations</font> are located</td>
    </tr>
    <tr>
      <td>Further, we expect to grow our <font color="blue">operations</font>, and our     needs for <font color="blue">additional</font> <font color="blue">management</font> and other <font color="blue">key personnel</font> are expected to     increase</td>
    </tr>
    <tr>
      <td>If we are not able to retain existing <font color="blue">key personnel</font>, or identify     and  hire  <font color="blue">additional</font> qualified personnel to meet expected growth, our     business could be <font color="blue">adversely</font> impacted</td>
    </tr>
    <tr>
      <td>We  <font color="blue">face risks</font> relating to our <font color="blue">international</font> sales, including inherent     economic, political and <font color="blue">regulatory</font> risks, which <font color="blue">could increase</font> our costs,     cause <font color="blue">interruptions</font> in our current business <font color="blue">operations</font> and/or stifle our     <font color="blue">growth opportunities</font></td>
    </tr>
    <tr>
      <td>Our products are sold <font color="blue">international</font>ly, primarily to our customers in Japan     and Europe</td>
    </tr>
    <tr>
      <td>We <font color="blue">currently sell</font> and market our <font color="blue">products by</font> channeling products     through  <font color="blue">distributor</font>  <font color="blue">organizations</font> and <font color="blue">sales agents</font></td>
    </tr>
    <tr>
      <td>Sales to foreign     customers accounted for 26prca, 29prca and 41prca of our net sales for the years     ended <font color="blue">December </font>31, 2005, 2004 and 2003, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">International </font>sales     are subject to inherent economic, political and <font color="blue">regulatory</font> risks, which     <font color="blue">could increase</font> our operating costs, cause <font color="blue">interruptions</font> in our current     business <font color="blue">operations</font> and impede our <font color="blue">international</font> growth</td>
    </tr>
    <tr>
      <td>These foreign risks     include, <font color="blue">among others</font>:       ·       <font color="blue">compliance with</font> new and changing <font color="blue">registration</font> <font color="blue">requirements</font>, our     <font color="blue">inability</font>  to  benefit  from <font color="blue">registration</font> for our product, inasmuch as     <font color="blue">registration</font>  may be <font color="blue">controlled by</font> a <font color="blue">distributor</font>, and tariffs or other     <font color="blue">barriers as</font> we continue to <font color="blue">expand into new countries</font> and <font color="blue">geographic regions</font>;       ·       exposure to currency exchange <font color="blue">fluctuations</font>, such as the 13prca and 14prca     decrease in value of the Euro and Yen, <font color="blue">respectively</font>, against the US dollar     for the year ended <font color="blue">December </font>31, 2005;       ·       <font color="blue">longer payment cycles</font> and <font color="blue">greater <font color="blue">difficult</font>y</font> in <font color="blue">accounts receivable</font>     <font color="blue">collection</font>;       ·       <font color="blue">reduced protection</font> for, and <font color="blue">enforcement</font> of, <font color="blue">intellectual</font> property     rights;       ·       political and <font color="blue">economic instability</font> in some of the regions where we     <font color="blue">currently sell</font> our products or that we <font color="blue">may expand into</font> in the future;       ·       <font color="blue">potentially</font> adverse tax consequences; and       ·        diversion of our products to the US <font color="blue">from products sold into</font>     <font color="blue">international</font> markets at lower prices</td>
    </tr>
    <tr>
      <td>Currently, all of our <font color="blue">international</font> sales are negotiated for and paid in     US dollars</td>
    </tr>
    <tr>
      <td>Nonetheless, these sales are subject to currency risks, since     changes in the values of <font color="blue">foreign currencies relative</font> to the value of the     US dollar can render our <font color="blue">products comparatively</font> more expensive</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">exchange rate</font> <font color="blue">fluctuations</font> could <font color="blue">negatively</font> impact <font color="blue">international</font> sales of     our products and our anticipated foreign <font color="blue">operations</font>, as could changes in the     general  economic  <font color="blue">conditions</font> in those markets</td>
    </tr>
    <tr>
      <td>In order to maintain a     <font color="blue">competitive</font> price for our products in Europe and Japan, we may have to     <font color="blue">provide discounts</font> or <font color="blue">otherwise <font color="blue">effective</font>ly reduce</font> our prices, resulting in a     <font color="blue">lower margin on products sold</font> in these <font color="blue">geographical territories</font></td>
    </tr>
    <tr>
      <td><font color="blue">Continued     </font>change  in  the values of the Euro, the Japanese Yen and other foreign     <font color="blue">currencies could</font> have a <font color="blue">negative impact on</font> our business, <font color="blue">financial condition</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We do not <font color="blue">currently hedge against <font color="blue">exchange rate</font></font>     <font color="blue">fluctuations</font>, which means that we will be <font color="blue">fully exposed</font> to <font color="blue">exchange rate</font>     changes</td>
    </tr>
    <tr>
      <td>Evolving regulation of <font color="blue">corporate governance</font> and <font color="blue"><font color="blue">public <font color="blue">disclosure</font></font> may</font> result     in <font color="blue">additional</font> expenses and <font color="blue">continuing <font color="blue">uncertainty</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font>laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font>     and <font color="blue">public <font color="blue">disclosure</font></font>, including the Sarbanes-Oxley Act of 2002, recent SEC     <font color="blue">regulations</font> and <font color="blue">Nasdaq Stock Market Inc</font></td>
    </tr>
    <tr>
      <td>rules and <font color="blue">regulations</font>, are creating     <font color="blue">significant</font> expenses and <font color="blue">uncertainty</font> for <font color="blue">companies such as ours</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>recent or       24     ______________________________________________________________________       changed  laws,  <font color="blue">regulations</font>  and  standards  are  subject  to  varying     <font color="blue">interpretations</font>, in many <font color="blue">cases due</font> to their lack of <font color="blue">specificity</font>, and as a     result, their <font color="blue">application</font> in <font color="blue">practice may evolve over</font> time <font color="blue">as new guidance</font>     is  provided  by <font color="blue">regulatory</font> and <font color="blue">governing bodies</font></td>
    </tr>
    <tr>
      <td>This could result in     continuing  <font color="blue">uncertainty</font>  regarding <font color="blue">compliance matters</font> and <font color="blue">higher costs</font>     <font color="blue">necessitated by ongoing revisions</font> to <font color="blue">disclosure</font> and <font color="blue">governance practices</font></td>
    </tr>
    <tr>
      <td>We     are committed to maintaining <font color="blue">high standards</font> of <font color="blue">corporate governance</font> and     <font color="blue">public <font color="blue">disclosure</font></font></td>
    </tr>
    <tr>
      <td>As a result, we intend to invest resources to <font color="blue">comply with</font>     evolving laws, <font color="blue">regulations</font> and standards, and this <font color="blue">investment</font> may result in     increased general and <font color="blue"><font color="blue">administrative</font> expenses</font> and a diversion of <font color="blue">management</font>     and <font color="blue">Board of Directors </font>time and attention from revenue-generating <font color="blue">activities</font>     and <font color="blue">operational oversight</font> to <font color="blue">compliance <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>If our efforts to comply     with  new  or  changed laws, <font color="blue">regulations</font> and <font color="blue">standards differ from</font> the     <font color="blue">activities</font>  intended  by  <font color="blue">regulatory</font>  or  <font color="blue">governing bodies</font>, <font color="blue">regulatory</font>     <font color="blue">authorities</font> or others may initiate legal <font color="blue">proceedings</font> <font color="blue">against us</font> and we may     be <font color="blue">adversely</font> impacted</td>
    </tr>
    <tr>
      <td>Investor confidence and share value may be <font color="blue">adversely</font> impacted if we and/or     our <font color="blue"><font color="blue">independent</font> registered <font color="blue">public <font color="blue">accounting</font> firm</font></font> conclude that our internal     <font color="blue">controls over financial</font> reporting are not <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>As  <font color="blue">directed by</font> Section 404 of the Sarbanes-Oxley Act of 2002, <font color="blue">the SEC     </font><font color="blue">adopted rules</font> requiring <font color="blue">public companies</font> to include a report of <font color="blue">management</font>     on our internal <font color="blue">controls over financial</font> reporting in our <font color="blue">Annual Report</font>s on     Form 10-K that contains an <font color="blue">assessment</font> by <font color="blue">management</font> of the <font color="blue">effective</font>ness of     our internal <font color="blue">controls over financial</font> reporting</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">independent</font>     <font color="blue">registered <font color="blue">public <font color="blue">accounting</font> firm</font> must attest</font> to and report on <font color="blue">management</font>’s     <font color="blue">assessment</font> as well as to the <font color="blue">effective</font>ness of our <font color="blue">internal controls over</font>     financial  reporting</td>
    </tr>
    <tr>
      <td>How  companies  are  <font color="blue">implementing</font>  these recent     <font color="blue">requirements</font>, including <font color="blue">internal control reforms</font>, if any, to <font color="blue">comply with</font>     Section 404’s <font color="blue">requirements</font>, and how <font color="blue">independent</font> registered public <font color="blue">accounting</font>     firms are applying these recent <font color="blue">requirements</font> and testing companies’ internal     controls, remain subject to <font color="blue">uncertainty</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">requirements</font> of Section 404 of     the Sarbanes-Oxley Act of 2002 are ongoing</td>
    </tr>
    <tr>
      <td>We expect that our internal     controls <font color="blue">will continue</font> to evolve as our business <font color="blue">activities</font> change</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>   we seek to <font color="blue">diligently</font> and <font color="blue">vigorously review</font> our <font color="blue">internal controls over</font>     financial reporting in an effort to ensure <font color="blue">compliance with</font> the Section 404     <font color="blue">requirements</font>, any control system, regardless of <font color="blue">how well designed</font>, operated     and evaluated, can <font color="blue">provide only reasonable</font>, not absolute, assurance that its     <font color="blue">objectives will</font> be met</td>
    </tr>
    <tr>
      <td>If, during any year, our <font color="blue">independent</font> registered     <font color="blue">public <font color="blue">accounting</font> firm</font> is not <font color="blue">satisfied with</font> our <font color="blue">internal controls over</font>     financial reporting or the <font color="blue">level at which</font> these controls are documented,     designed, operated, tested or assessed, or if the <font color="blue">independent</font> registered     <font color="blue">public <font color="blue">accounting</font> firm</font> interprets the <font color="blue">requirements</font>, rules or <font color="blue">regulations</font>     <font color="blue">differently</font>  than we do, then it may decline to attest to <font color="blue">management</font>’s     <font color="blue">assessment</font> or may issue a report that is qualified</td>
    </tr>
    <tr>
      <td>This could result in an     <font color="blue">adverse reaction</font> in the <font color="blue">financial marketplace due</font> to a loss of investor     confidence in the re<font color="blue">liability</font> of our <font color="blue">financial statements</font> and <font color="blue">effective</font>ness     of our internal controls, which ultimately could <font color="blue">negatively</font> impact the     <font color="blue">market price</font> of our shares</td>
    </tr>
    <tr>
      <td>Future changes in <font color="blue">financial <font color="blue"><font color="blue">accounting</font> standards</font></font> or practices or existing     <font color="blue">taxation rules</font> or <font color="blue">practices may affect</font> our reported results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>A  change in <font color="blue"><font color="blue">accounting</font> standards</font> or practices or a change in existing     <font color="blue">taxation rules</font> or practices can have a <font color="blue">significant</font> effect on our reported     results and <font color="blue">may even affect</font> our reporting of <font color="blue">transactions</font> completed before     the  change  is  <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>New <font color="blue"><font color="blue">accounting</font> pronouncements</font> and taxation     rules and varying <font color="blue">interpretations</font> of <font color="blue"><font color="blue">accounting</font> pronouncements</font> and taxation     practices have occurred and may occur in the future</td>
    </tr>
    <tr>
      <td>Changes to existing     rules or the questioning of current practices may <font color="blue">adversely</font> affect our     reported financial results or the way we conduct our business</td>
    </tr>
    <tr>
      <td>For example,     changes have <font color="blue">been approved by</font> the Financial Accounting Standards Board, or     FASB, that require that we <font color="blue">record compensation expense</font> in our statements of     <font color="blue">operations</font> for <font color="blue">equity compensation instruments</font>, including employee and     director <font color="blue">stock options</font>, using the <font color="blue">fair value method</font></td>
    </tr>
    <tr>
      <td>Although there will be     no change in our <font color="blue">total cash flows</font>, our reported financial results beginning     in the <font color="blue">first quarter</font> of 2006 will be <font color="blue">negatively</font> and <font color="blue">materially</font> impacted by     this  <font color="blue">accounting</font>  change</td>
    </tr>
    <tr>
      <td>Other potential changes in <font color="blue">existing taxation</font>     rules related to <font color="blue">stock options</font> and other forms of <font color="blue">equity compensation could</font>     also have a <font color="blue">significant</font> negative effect on our reported results</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________       Risks Related to Our Common Stock       Our stock price has <font color="blue">been highly volatile</font>, and an <font color="blue">investment</font> in our stock     <font color="blue">could suffer</font> a <font color="blue">significant</font> decline in value</td>
    </tr>
    <tr>
      <td>The  <font color="blue">market price</font> of our <font color="blue">common stock</font> has <font color="blue">been highly volatile</font> and has     <font color="blue">fluctuated substantially</font> in the past</td>
    </tr>
    <tr>
      <td>For example, between <font color="blue">December </font>31, 2004     and <font color="blue">December </font>31, 2005, the closing price of our <font color="blue">common stock</font>, as reported on     the Nasdaq National Market System, has <font color="blue">ranged from</font> a low of dlra3dtta55 to a high     of dlra15dtta51</td>
    </tr>
    <tr>
      <td>We expect our <font color="blue">common stock</font> to continue to be subject to wide     <font color="blue">fluctuations</font> in price in response to <font color="blue">various factors</font>, many of which are     beyond our control, including:       ·       <font color="blue">seasonal <font color="blue">fluctuations</font></font> in our sales of <font color="blue">Group A Strep </font>and influenza     tests, which are <font color="blue">generally</font> highest in fall and winter, thus resulting in     <font color="blue">generally</font> lower operating results in the second and <font color="blue">third calendar quarters</font>     and higher operating results in the first and <font color="blue">fourth calendar quarters</font>;       ·       <font color="blue">recent media attention focused on</font> a <font color="blue">potential influenza pandemic</font> and     the  related potential impact on humans from avian flu, as well as the     <font color="blue"><font color="blue">uncertainty</font> surrounding</font> the <font color="blue">detection</font> of H5N1 in human specimens;       ·       changes in the level of competition, such as would occur if one of     our larger and <font color="blue">better financed <font color="blue">competitors</font> introduced</font> a new or lower priced     product to <font color="blue"><font color="blue">compete with</font> one</font> of our products;       ·       changes in <font color="blue">economic <font color="blue">conditions</font></font> in our domestic and <font color="blue">international</font>     markets, such as economic downturns, reduced consumer demand, inflation and     <font color="blue">currency <font color="blue">fluctuations</font></font>, particularly as we <font color="blue">expand into markets outside</font> Japan     and  Western  Europe  where  <font color="blue">economic <font color="blue">conditions</font></font> may differ from those     <font color="blue">prevailing at given times among</font> developed nations;       ·       changes in sales levels, since a <font color="blue">significant</font> portion of our costs     are fixed <font color="blue">costs with</font> the result that <font color="blue"><font color="blue">relatively</font> higher <font color="blue">sales could</font> likely</font>     increase <font color="blue">profitability</font> but <font color="blue">relatively</font> lower sales would not <font color="blue">reduce costs by</font>     the <font color="blue">same proportion</font>, and <font color="blue">hence could</font> cause operating losses;       ·       declines in orders from major <font color="blue">distributor</font>s as a result of lower than     expected end-user demand, whether as a result of a light cold and flu season     or otherwise;       ·       lower than anticipated sales of our <font color="blue">new products</font>;       ·        our failure to achieve, or changes in, financial estimates by     <font color="blue">securities analysts</font> and comments or opinions about us by <font color="blue">securities analysts</font>     or <font color="blue">major <font color="blue">stockholders</font></font>;       ·       <font color="blue">additions</font> or <font color="blue">departures</font> of our <font color="blue">key personnel</font>;       ·       <font color="blue">litigation</font> or threat of <font color="blue">litigation</font>;       ·       sales of our <font color="blue">common stock</font> and limited <font color="blue">daily trading volume</font>; and       ·       economic and other external factors, disasters or crises</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general, and the Nasdaq National Market     System  and  the  market  for <font color="blue">technology</font> companies in particular, have     experienced <font color="blue">significant</font> price and volume <font color="blue">fluctuations</font> that, at times, have     been unrelated or <font color="blue">disproportionate</font> to the operating performance of the     <font color="blue">relevant companies</font></td>
    </tr>
    <tr>
      <td>In the past, following periods of <font color="blue">volatility</font> in the     <font color="blue">market price</font> of a company’s securities, securities class action <font color="blue">litigation</font>     has <font color="blue">often been instituted</font></td>
    </tr>
    <tr>
      <td>A securities class action suit <font color="blue">against us</font> could     result in substantial costs, potential liabilities and the diversion of     <font color="blue">management</font>’s attention and resources</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________       Future <font color="blue">sales by existing <font color="blue">stockholders</font> could depress</font> the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Sales of our <font color="blue">common stock</font> in the <font color="blue">public market</font>, or the <font color="blue">perception</font> that such     <font color="blue">sales could</font> occur, could <font color="blue">negatively</font> impact the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005:       ·       <font color="blue">approximately</font> 33dtta8 million shares of our <font color="blue">common stock</font> had been     issued in <font color="blue">registered offerings</font> and 33dtta2 million are <font color="blue">freely tradable</font> in the     <font color="blue">public market</font>s, and 0dtta6 million relate to <font color="blue">restricted shares</font>;       ·       <font color="blue">approximately</font> 2dtta5 million shares of our <font color="blue">common stock</font> were issuable     upon  exercise  of  outstanding <font color="blue">stock options</font> under our <font color="blue">various equity</font>     incentive plans at a <font color="blue">weighted average exercise price</font> of dlra5dtta09, for stock     options; and       ·       we had in effect <font color="blue">registration</font> statements under the <font color="blue">Securities Act </font>of     1933 <font color="blue">registering</font> <font color="blue">approximately</font> 4dtta3 million shares of <font color="blue">common stock</font> reserved     under our equity incentive plan</td>
    </tr>
    <tr>
      <td>In addition, there were 213cmam077 shares     <font color="blue">reserved under</font> our <font color="blue">employee stock purchase</font> plan</td>
    </tr>
    <tr>
      <td>We are unable to estimate the number of shares of our <font color="blue">common stock</font> that may     actually be resold in the <font color="blue">public market</font> since this <font color="blue">will depend on</font> the market     price for our <font color="blue">common stock</font>, the individual <font color="blue">circumstances</font> of the sellers and     other factors</td>
    </tr>
    <tr>
      <td>We also have a number of <font color="blue">institutional <font color="blue">stockholders</font></font> that own     <font color="blue">significant</font> blocks of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If one or more of these <font color="blue">stockholders</font>     were to sell large portions of their holdings in a <font color="blue">relatively</font> short time,     for liquidity or other reasons, the prevailing <font color="blue">market price</font> of our common     <font color="blue">stock could</font> be <font color="blue">negatively</font> affected</td>
    </tr>
    <tr>
      <td>Anti-takeover <font color="blue">devices may prevent</font> a sale, or changes in the <font color="blue">management</font>, of     the Company</td>
    </tr>
    <tr>
      <td>We have in place several anti-takeover devices, including a stockholder     rights plan, that may have the effect of delaying or preventing a sale, or     changes in the <font color="blue">management</font>, of the Company</td>
    </tr>
    <tr>
      <td>For example, our bylaws require     <font color="blue">stockholders</font> to <font color="blue">give written</font> notice of any proposal or <font color="blue">director nomination</font>     to us within a <font color="blue">specified period</font> of time prior to any <font color="blue">stockholder meeting</font></td>
    </tr>
    <tr>
      <td>We may also issue shares of <font color="blue">preferred stock without stockholder approval</font> and     on  terms that our <font color="blue">Board of Directors </font>may determine in the future</td>
    </tr>
    <tr>
      <td>The     issuance  of  preferred  <font color="blue">stock could</font> have the effect of making it more     <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our <font color="blue">outstanding stock</font>,     and  the  holders of such preferred <font color="blue">stock could</font> have voting, dividend,     <font color="blue">liquidation</font>, and other rights superior to those of holders of our common     stock</td>
    </tr>
    <tr>
      <td>We do not <font color="blue">pay dividends</font> and this may <font color="blue">negatively</font> affect the price of our     stock</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">paid <font color="blue">dividends on</font></font> our <font color="blue">common stock</font> and do not anticipate paying     <font color="blue">dividends on</font> our <font color="blue">common stock</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">future price</font> of     our <font color="blue">common stock</font> may be <font color="blue">adversely</font> impacted because we have not paid and do     not anticipate <font color="blue">paying dividends</font></td>
    </tr>
  </tbody>
</table>